肝胆胰外科杂志 ›› 2016, Vol. 28 ›› Issue (6): 441-447.doi: 10.11952/j.issn.1007-1954.2016.06.001

• 专家笔谈 • 上一篇    下一篇

三氧化二砷治疗肝癌的出路—联合用药

彭贵主1, 叶啟发1,2(), 王垒1   

  1. 1.武汉大学中南医院 武汉大学肝胆疾病研究院/武汉大学移植中心/移植医学技术湖北省重点实验室,湖北 武汉 430071
    2.中南大学湘雅三医院 卫生部移植医学工程技术研究中心,湖南 长沙 410013
  • 收稿日期:2016-04-15 出版日期:2016-11-25 发布日期:2016-11-25
  • 作者简介:

    [第一作者简介] 彭贵主(1961-),男,江西余干人,硕士,教授,主任医师,硕士生导师。

  • 基金资助:
    国家自然科学基金新疆联合基金项目(U1403222);湖北省武汉市科技局项目(20160601010033)

  • Received:2016-04-15 Online:2016-11-25 Published:2016-11-25

关键词: 三氧化二砷, 肝癌, 中药, 免疫调节

中图分类号: 

  • R735.7
[1] EMADI A, GORE S D.Arsenic trioxide —— an old drug re-discovered[J]. Blood Rev, 2010, 24(4-5): 191-199.
[2] ZHOU J.Arsenic trioxide: an ancient drug revived[J]. Chin Med J (Engl), 2012, 125(19): 3556-3560.
[3] KIM E Y, LEE S S, SHIN J H, et al.Anticancer effect of arse-nic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model[J]. Clin Exp Med, 2014, 14(2): 215-224.
[4] LEE J C, LEE H Y, MOON C H, et al.Arsenic trioxide as a vascular disrupting agent: synergistic effect with irinotecan on tumor growth delay in a CT26 allograft model[J]. Transl Oncol, 2013, 6(1): 83-91.
[5] SIDES M D, SOSULSKI M L, LUO F, et al.Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma[J]. Vi-rol J, 2013, 10: 152.
[6] HE X, YANG K, CHEN P, et al.Arsenic trioxide-based thera-py in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review[J]. Onco Targets Ther, 2014, 7: 1593-1599.
[7] KERL K, MORENO N, HOLSTEN T, et al.Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1[J]. Int J Cancer, 2014, 135(4): 989-995.
[8] CHEN W, ZHENG R, BAADE P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[9] JIAO Y H, ZHANG Q, PAN L L, et al.Rat liver mitochondri-al dysfunction induced by an organic arsenical compound 4-(2-Nitrobenzaliminyl) phenyl arsenoxide[J]. J Membr Biol, 2015, 248(6): 1071-1078.
[10] KITO M, AKAO Y, OHISHI N, et al.Arsenic trioxide-indu-ced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines[J]. Biochem Biophys Res Commun, 2002, 291(4): 861-867.
[11] KITO M, MATSUMOTO K, WADA N, et al.Antitumor effect of arsenic trioxide in murine xenograft model[J]. Cancer Sci, 2003, 94(11): 1010-1014.
[12] HUA H, QIN S, RUI J, et al.Pharmacokinetics of arsenic tri-oxide (As(2)O(3)) in Chinese primary hepatocarcinoma pa-tients[J]. Asian Pac J Cancer Prev, 2011, 12(1): 61-65.
[13] XU H Y, YANG Y L, LIU S M, et al.Effect of arsenic trioxide on human hepatocarcinoma in nude mice[J]. World J Gastro-enterol, 2004, 10(24): 3677-3679.
[14] YOO D R, CHONG S A, NAM M J.Proteome profiling of ar-senic trioxide-treated human hepatic cancer cells[J]. Cancer Genomics Proteomics, 2009, 6(5): 269-274.
[15] ZHAO W, HU Y N, JIANG X J, et al.The apoptotic mecha-nism of hepatocellular carcinoma cell line (HepG2) induced by arsenic trioxide[J]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2014, 45(5): 739-743.
[16] 于浩, 姜洪磊, 许东, 等. 三氧化二砷对不同肝癌细胞系凋亡的影响[J]. 生物医学工程与临床, 2016(1): 83-86.
[17] ALARIFI S, ALI D, ALKAHTANI S, et al.Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepato-cellular carcinoma cells[J]. Onco Targets Ther, 2013, 6: 75-84.
[18] ZHANG X, JIA S, YANG S, et al.Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression[J]. J Cell Biochem, 2012, 113(11): 3528-3535.
[19] JIANG F, WANG X, LIU Q, et al.Inhibition of TGF-beta/SMAD3/NF-kappaB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells[J]. Toxicol Lett, 2014, 231(1): 55-61.
[20] TUNG J N, ChENG Y W, HSU C H, et al. Normoxically overexpressed hypoxia inducible factor 1-alpha is involved in arsenic trioxide resistance acquisition in hepatocellular carci-noma[J]. Ann Surg Oncol, 2011, 18(5): 1492-1500.
[21] ZhANG S, ZHOU J, ZHANG C, et al. Arsenic trioxide in-hibits HCCLM3 cells invasion through de novo ceramide syn-thesis and sphingomyelinase-induced ceramide production[J]. Med Oncol, 2012, 29(3): 2251-2260.
[22] LI H Y, CAO L M.Inhibitory effect of arsenic trioxide on in-vasion in human hepatocellular carcinoma SMMC-7721 cells and its mechanism[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2012, 28(12): 1254-1257.
[23] WANG X, JIANG F, MU J, et al.Arsenic trioxide attenu-ates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491[J]. Toxicol Lett,2014, 227(2): 75-83.
[24] WANG G Z, ZHANG W, FANG Z T, et al.Arsenic trioxide:marked suppression of tumor metastasis potential by inhibit-ing the transcription factor Twist in vivo and in vitro[J]. J Cancer Res Clin Oncol, 2014, 140(7): 1125-1136.
[25] 唐印华, 王玺, 梁桃, 等. As2O3抑制人肝癌细胞侵袭及转移的实验研究[J]. 哈尔滨医科大学学报, 2013(1): 24-27.
[26] EAVES C J.Cancer stem cells: Here, there, everywhere[J]. Nature, 2008, 456(7222): 581-582.
[27] BHOLA N E, BALKO J M, DUGGER T C, et al.TGF-beta inhibition enhances chemotherapy action against triple-nega-tive breast cancer[J]. J Clin Invest, 2013, 123(3): 1348-1358.
[28] VIDAL S J, RODRIGUEZ-BRAVO V, GALSKY M, et al.Targeting cancer stem cells to suppress acquired chemotherapy resistance[J]. Oncogene, 2014, 33(36): 4451-4463.
[29] ZHANG K Z, ZHANG Q B, ZHANG Q B, et al.Arsenic tri-oxide induces differentiation of CD133+ hepatocellular carci-noma cells and prolongs posthepatectomy survival by target-ing GLI1 expression in a mouse model[J]. J Hematol Oncol, 2014, 7: 28.
[30] TOMULEASE C, SORITAU O, FISCHER-FOROR E, et al.Arsenic trioxide plus cisplatin/interferon alpha-2b/doxorubi-cin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma[J]. Hematol Oncol Stem Cell Ther, 2011, 4(2): 60-66.
[31] LI Y, JIANG F, LIU Q, et al.Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the at-tenuation of endogenous transforming growth factor beta sig-nal[J]. Toxicol Sci, 2015, 143(1): 156-164.
[32] ZHANG X, YANG X R, SUN C, et al.Promyelocytic leuke-mia protein induces arsenic trioxide resistance through regula-tion of aldehyde dehydrogenase 3 family member A1 in hepa-tocellular carcinoma[J]. Cancer Lett, 2015, 366(1): 112-122.
[33] CHEN X, ZHANG M, LIU L X.The overexpression of mul-tidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells[J]. Oncol Rep, 2009, 22(1): 73-80.
[34] Lin C C, Hsu C, Hsu C H, et al.Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial[J]. Invest New Drugs, 2007, 25(1): 77-84.
[35] ZHENG T, YIN D, LU Z, et al.Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in hepatocellular carcinoma[J]. Mol Cancer, 2014, 13:133.
[36] ARDALAN B, SUBBARAYAN P R, Ramos Y, et al.A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma[J]. Clin Cancer Res, 2010, 16(11): 3019-3027.
[37] HAO L, ZHAO J, WANG X, et al.Hepatotoxicity from arse-nic trioxide for pediatric acute promyelocytic leukemia[J]. J Pediatr Hematol Oncol, 2013, 35(2): e67-e70.
[38] JIAO Y H, ZHANG Q, PAN L L, et al.Rat liver mitochon-drial dysfunction induced by an organic arsenical com-pound 4-(2-Nitrobenzaliminyl) Phenyl Arsenoxide[J]. J Membr Biol, 2015, 248(6): 1071-1078.
[39] ROSOMORDUC O, CHEVREAU C, DIELENSEGER P, et al.Use of sorafenib in patients with hepatocellular or renal carci-noma[J]. Gastroenterol Clin Biol, 2010, 34(3): 161-167.
[40] SHAN J, SHEN J, LIU L, et al.Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma[J]. Hepatology, 2012, 56(3): 1004-1014.
[41] BLIVET-VAN E M, CHETTOUH H, FARTOUX L, et al.Epidermal growth factor receptor and HER-3 restrict cell re-sponse to sorafenib in hepatocellular carcinoma cells[J]. J Hepatol, 2012, 57(1): 108-115.
[42] CHEN H C, JENG Y M, YUAN R H, et al.SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocel-lular carcinoma and its expression predicts poor prognosis[J]. Ann Surg Oncol, 2012, 19(6): 2011-2019.
[43] RANGWALA F, WILLIAMS K P, SMITH G R, et al.Differ-ential effects of arsenic trioxide on chemosensitization in hu-man hepatic tumor and stellate cell lines[J]. BMC Cancer, 2012, 12: 402.
[44] YANG X, SUN D, TIAN Y, et al.Metformin sensitizes hepa-tocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression[J]. Tumour Biol, 2015, 36(4): 2957-2964.
[45] WEI J, YE C, LIU F, et al.All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concen-trations of calcium in hepatocellular carcinoma cells[J]. J Chemother, 2014, 26(6): 348-352.
[46] 唐洁, 王川, 姜政. 水通道蛋白9表达水平影响HepG2肝癌细胞的生物学行为及对As2O3的敏感性[J]. 细胞与分子免疫学杂志, 2015, (6): 769-774.
[47] CHEN C, ZHANG Y, WANG Y, et al.Synergic effect of 3’-azido-3’-deoxythymidine and arsenic trioxide in suppress-ing hepatoma cells[J]. Anticancer Drugs, 2011, 22(5): 435-443.
[48] SHEN P, JIANG T, LU H, et al.Combination of Poly I: C and arsenic trioxide triggers apoptosis synergistically via activa-tion of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells[J]. Cell Biol Int, 2011, 35(8): 803-810.
[49] LUO Q, LI Y, DENG J, et al.PARP-1 inhibitor sensitizes ar-senic trioxide in hepatocellular carcinoma cells via abroga-tion of G2/M checkpoint and suppression of DNA damage re-pair[J]. Chem Biol Interact, 2015, 226: 12-22.
[50] LUO Q, LI Y, LAI Y, et al.The role of NF-kappaB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells[J]. J Toxicol Sci,2015, 40(3): 349-363.
[51] LIU Z M, TSENG J T, HONG D Y, et al.Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells[J]. Biochem J, 2011, 438(2): 349-358.
[52] RABELLINO A, SCAGLIONI P P.PML degradation:multi-ple ways to eliminate PML[J]. Front Oncol, 2013, 3: 60.
[53] ZHAO X Y, YANG S, CHEN Y R, et al.Resveratrol and arse-nic trioxide act synergistically to kill tumor cells in vitro and in vivo[J]. PLoS One, 2014, 9(6): e98925.
[54] LI W, WANG M, WANG L, et al.Icariin synergizes with ar-senic trioxide to suppress human hepatocellular carcinoma[J]. Cell Biochem Biophys, 2014, 68(2): 427-436.
[55] CHEN G, WANG K, YANG B Y, et al.Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular car-cinoma cells[J]. Int J Oncol, 2012, 40(1): 139-147.
[56] JIANG H, MA Y, CHEN X, et al.Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma[J]. Cancer Sci, 2010, 101(4): 975-983.
[57] MA Y, WANG J, LIU L, et al.Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB[J]. Cancer Lett, 2011, 301(1): 75-84.
[58] LIU L, CHEN B A, QIN S K.Anti-angiogenesis effect of ar-senic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2011, 31(1): 67-72.
[59] 倪珊珊, 廖广辉, 张广顺, 等. 三氧化二砷与隐丹参酮不同配比对人肝癌HepG2裸鼠移植瘤的抑制作用[J]. 浙江中医药大学学报, 2015(1): 62-66.
[60] DIEPART C, KARROUM O, MAGAT J, et al.Arsenic triox-ide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors[J]. Cancer Res, 2012,72(2): 482-490.
[61] HINES-PERALTA A, SUKHATME V, REGAN M, et al.Im-proved tumor destruction with arsenic trioxide and radiofre-quency ablation in three animal models[J]. Radiology, 2006, 240(1): 82-89.
[62] KIM H Y, PARK J W.Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future[J]. Liver Cancer, 2014, 3(1): 9-17.
[63] LI H, GONG J, JIANG X, et al.Arsenic trioxide treatment of rabbit liver VX-2 carcinoma via hepatic arterial cannulation-induced apoptosis and decreased levels of survivin in the tu-mor tissue[J]. Croat Med J, 2013, 54(1): 12-16.
[64] WANG H, LIU Y, WANG X, et al.Randomized clinical con-trol study of locoregional therapy combined with arsenic tri-oxide for the treatment of hepatocellular carcinoma[J]. Cancer, 2015, 121(17): 2917-2925.
[65] SEONG N J, YOON C J, KANG S G, et al.Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: intra-arterial versus intravenous administration[J]. Korean J Radiol. 2012, 13(2): 195-201.
[66] KOLODKIN-GAL D, EDDEN Y, HARTSHTARK Z, et al.Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect[J]. Gene Ther, 2009, 16(7): 905-915.
[67] 杨雅雯, 刘丹, 刘婷, 等. 三氧化二砷粉针剂联合重组腺病毒介导的IκBαM治疗肝癌[J]. 世界华人消化杂志, 2013(13): 1159-1163.
[68] CUI L, ZHANG S, ZHANG W, et al.Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically in-hibit in vitro and in vivo growth of a hepatoma cell line[J]. Oncol Res, 2010, 18(7): 305-314.
[69] SRIVASTAVA S, RIEEDLL S R.Engineering CAR-T cells: Design concepts[J]. Trends Immunol, 2015, 36(8): 494-502.
[70] GRUPP S A, KALOS M, BARRETT D, et al.Chimeric an-tigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013, 368(16): 1509-1518.
[71] GAO H, LI K, TU H, et al.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(24): 6418-6428.
[72] ZHENG Y, DOU Y, DUAN L, et al.Using chemo-drugs or ir-radiation to break immune tolerance and facilitate immuno-therapy in solid cancer[J]. Cell Immunol, 2015, 294(1): 54-59.
[73] LI F, GUO Z, LIZEE G, et al.Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellu-lar carcinoma patients[J]. Clin Chem Lab Med, 2014, 52(9): 1357-1365.
[74] HUANG Y, WANG F, WANG Y, et al.Intrahepatic interleu-kin-17+ T cells and FoxP3+ regulatory T cells cooperate topromote development and affect the prognosis of hepatocellu-lar carcinoma[J]. J Gastroenterol Hepatol, 2014, 29(4): 851-859.
[75] THOMAS-SCHOEMANN A, BATTEUX F, MONGARET C, et al.Arsenic trioxide exerts antitumor activity through regu-latory T cell depletion mediated by oxidative stress in a mu-rine model of colon cancer[J]. J Immunol, 2012, 189(11): 5171-5177.
[76] POWELL B L.Arsenic trioxide in acute promyelocytic leuke-mia: potion not poison[J]. Expert Rev Anticancer Ther, 2011, 11(9): 1317-1319.
[77] RAO Y, LI R, ZHANG D.A drug from poison: how the ther-apeutic effect of arsenic trioxide on acute promyelocytic leu-kemia was discovered[J]. Sci China Life Sci, 2013, 56(6): 495-502.
[78] LAU A, ZHENG Y, TAO S, et al.Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner[J]. Mol Cell Biol, 2013, 33(12): 2436-2446.
[79] MIAO Z, WU L, LU M, et al.Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methyla-tion of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic[J]. Oncotarget, 2015, 6(25): 21493-21506.
[1] 丁兢, 邸亮, 李聪, 赵晓飞, 郭庆良, 马超. 术前血清VEGF和IL-12水平对原发性肝癌腹腔镜肝切除术预后的影响[J]. 肝胆胰外科杂志, 2023, 35(8): 459-463.
[2] 范祺, 倪彦彬, 高杰, 朱继业, 李照.
原发性肝癌术后复发再次肝切除的疗效分析
[J]. 肝胆胰外科杂志, 2023, 35(7): 390-396.
[3] 陈怡, 牟弘毅, 李雪艳, 陈朝红.
基于ERAS理念的静脉血栓栓塞症预防方案在肝癌围手术期的应用
[J]. 肝胆胰外科杂志, 2023, 35(7): 397-400,406.
[4] 高忠嵩, 贾科峰.
TACE治疗肝细胞癌的现状及在2022版BCLC策略中的更新
[J]. 肝胆胰外科杂志, 2023, 35(6): 326-330.
[5] 赵健萍, 张必翔, 张志伟, 王其.
血管介入在肝癌中的应用
[J]. 肝胆胰外科杂志, 2023, 35(6): 331-336.
[6] 蔡慧欣, 项思博, 杨文军. VAVs基因家族在肝癌中的表达及临床意义[J]. 肝胆胰外科杂志, 2023, 35(6): 366-373.
[7] 翟博.
肝癌局部消融术:体系建设与价值提升
[J]. 肝胆胰外科杂志, 2023, 35(5): 257-262.
[8] 周鹏宇, 李佳霖, 段清垚, 涂志坚, 雷晓华, 贺军, 陈国栋.
基于倾向性评分匹配的ERAS在原发性肝癌肝切除围手术期的应用
[J]. 肝胆胰外科杂志, 2023, 35(3): 134-139.
[9] 房达, 马良, 杜宁, 赵隶嬴, 赵乾, 高文峰, 袁春旺.
经桡动脉与股动脉行肝动脉化疗栓塞术患者接受的辐射剂量比较
[J]. 肝胆胰外科杂志, 2023, 35(12): 753-756.
[10] 江振辉, 胡晓川, 吴文明, 程斌, 陈晓鹏.
肝癌术后预后列线图的建立和验证
[J]. 肝胆胰外科杂志, 2023, 35(11): 649-659.
[11] 卢建利, 贺伟, 刘进衡.
经PTCD与ENBD置管冷却技术预防肝癌微波消融术胆管热损伤的效果对比
[J]. 肝胆胰外科杂志, 2023, 35(11): 668-673.
[12] 赵飞, 李刚.
工程化外泌体在肝癌治疗中的研究进展
[J]. 肝胆胰外科杂志, 2023, 35(11): 697-700,封三.
[13] 申雪晗, 周江敏, 张志伟, 陈孝平. NLR对TACE联合仑伐替尼及免疫治疗的中晚期肝癌患者预后的预测价值[J]. 肝胆胰外科杂志, 2023, 35(1): 19-24.
[14] 李晓举 , 王星入 , 万丹丹 , 刘天锡.
三维可视化联合术中超声在腹腔镜肝癌切除患者中的近期效果
[J]. 肝胆胰外科杂志, 2023, 35(1): 30-35.
[15] 周少来, 周俭. 肝癌复发转移的防治[J]. 肝胆胰外科杂志, 2022, 34(7): 385-388.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © 2017 肝胆胰外科杂志 All Rights Reserved.
电话/传真:0577-86699363 E-mail: gdywkzz@vip.126.com
地址:浙江省温州市茶山高教园区温州医科大学图书馆A411室 邮编:325035
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn